Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review

Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH56383FSA
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Evotec AG (EVT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and Munich, Germany; South San Francisco, Branford and Princeton, the US; and Toulouse, France. Evotec is headquartered in Hamburg, Germany.

Evotec AG Key Recent Developments

Jul 04,2018: Sanofi integrates infectious disease unit into Evotec

Jun 25,2018: Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi

May 31,2018: Arix Bioscience Forms Strategic Collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to Foster New Companies in Cancer and Infectious Diseases

May 31,2018: Evotec forms academic BRIDGE 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center

May 09,2018: Evotec Reports First Quarter 2018 Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Evotec AG-Key Facts 6

Evotec AG-Key Employees 7

Evotec AG-Key Employee Biographies 8

Evotec AG-Major Products and Services 9

Evotec AG-History 10

Evotec AG-Company Statement 19

Evotec AG-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Joint Venture 21

Section 2-Company Analysis 22

Company Overview 22

Evotec AG-Business Description 23

Business Segment: EVT Execute Segment 23

Overview 23

Performance 23

Business Segment: EVT Innovate Segment 23

Overview 23

Performance 23

R&D Overview 24

Evotec AG-SWOT Analysis 25

SWOT Analysis-Overview 25

Evotec AG-Strengths 25

Evotec AG-Weaknesses 26

Evotec AG-Opportunities 27

Evotec AG-Threats 28

Evotec AG-Key Competitors 29

Section 3-Company Financial Ratios 30

Financial Ratios-Capital Market Ratios 30

Financial Ratios-Annual Ratios 31

Performance Chart 34

Financial Performance 34

Financial Ratios-Interim Ratios 35

Financial Ratios-Ratio Charts 36

Section 4-Company's Lifesciences Financial Deals and Alliances 37

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37

Evotec AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38

Evotec AG, Recent Deals Summary 39

Section 5-Company's Recent Developments 40

Jul 04, 2018: Sanofi integrates infectious disease unit into Evotec 40

Jun 25, 2018: Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi 41

May 31, 2018: Arix Bioscience Forms Strategic Collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to Foster New Companies in Cancer and Infectious Diseases 42

May 31, 2018: Evotec forms academic BRIDGE 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center 43

May 09, 2018: Evotec Reports First Quarter 2018 Results and Provides Corporate Update 44

May 02, 2018: Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics 46

Mar 27, 2018: Evotec plans conversion into European Company (SE) 47

Mar 26, 2018: Evotec Launches INDIGO, A Unique Integrated Drug Development Solution for Accelerating Early Drug Candidates into the Clinic 48

Feb 28, 2018: Novo Holdings announce Launch of REPAIR and formation of scientific selection board 49

Jan 08, 2018: Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi 50

Section 6-Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Evotec AG, Performance Chart (2013-2017) 34

Evotec AG, Ratio Charts 36

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37

Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 38

List of Tables

Evotec AG, Key Facts 6

Evotec AG, Key Employees 7

Evotec AG, Key Employee Biographies 8

Evotec AG, Major Products and Services 9

Evotec AG, History 10

Evotec AG, Subsidiaries 20

Evotec AG, Joint Venture 21

Evotec AG, Key Competitors 29

Evotec AG, Ratios based on current share price 30

Evotec AG, Annual Ratios 31

Evotec AG, Annual Ratios (Cont...1) 32

Evotec AG, Annual Ratios (Cont...2) 33

Evotec AG, Interim Ratios 35

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37

Evotec AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38

Evotec AG, Recent Deals Summary 39

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pharmaceutical Product Development LLC

Covance Inc

Cobra Biologics Ltd

Charles River Germany GmbH & Co. KG

Almac Group Ltd

Albany Molecular Research Inc

Evotec AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8599
Site License
USD 250 INR 17198
Corporate User License
USD 375 INR 25796

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com